Anti-â Glycoprotein-I Antibody in Acute Myocardial Infarction

Abstract

Problem statement: Ischemic cardiac manifestations have been reported in a various percentage of patients with anti-phospholipid antibodies. Data concerning the relation between anti-Phospholipid (aPL) antibodies and myocardial infarction in subjects without evidence of overt autoimmune disease are conflicting. Anti-beta2 glycoprotein-I (anti-beta2-GPI) antibody is detected in various diseases like rheumatoid arthritis, systemic lupus erythematosus and anti-phospholipid antibody syndrome. The study of anti-beta2-GPI antibody in Acute Myocardial Infarction (AMI) might shed light on etiologic mechanisms in the pathogenesis of acute coronary syndromes. The purpose of the present study was to determine association of plasma aPL antibodies, namely, anti-beta2-GPI antibodies, with AMI. This study was designed to investigate whether prevalence of anti-beta2-GPI antibodies, in patients who had acute myocardial infarction and to analyze their relationship with traditional cardiovascular risk factors. Approach: We investigated the prevalence of anti-beta2-GPI IgG in a well characterized group of patients with AMI as a case group. Sera from 74 patients with AMI and from 76 healthy subjects, matched for age and sex as a control group. Using ELISA to evaluate the presence of IgG isotype of anti-beta2-GPI autoantibodies in their sera. Results: The prevalence of anti-beta2-GPI IgG in the control group (10.50%) resulted significantly lower than in patients with AMI (37.80%) (p<0.005). There was significant difference between positive anti-β2-GPI test in patients with STEMI and those with NSTEMI (66.7% Vs 36.4%), (p = 0.020). Conclusion: Our findings suggest that anti-beta2-GPI IgG antibodies seemed to behave as independent risk factors for myocardial infarction, which may represent a link between autoimmunity and atherosclerosis in patients with acute myocardial infarction. Further studies with bigger patients are needed to explore association of anti-β2-GPI IgG with STEMI and NSTEMI.

A Comparative Study of Anti-Phosphatidyl Inositole Antibodies in Patients With Myocardial Infarction and Healthy Subjects

“…There was not found correlation between anti-PI Abs (IgG, IgM) and standard cardiovascular risk factors such as smoking, hypertension and diabetes which is agreement with previous studies (Shojaie and Jahromi, 2011;Jahromi et al, 2010a;2010b;2013b;2013c).…”

“…Other aPLs have been reported to have association with CAD and AMI (Shojaie and Jahromi, 2011;Jafarzadeh et al, 2011;Greco et al, 2010;Urbanus et al, 2009;Jahromi et al, 2013b;2013c).…”

“…The results of some studies also demonstrated an association between anti-PL Ab and Ischemic Heart Disease (IHD) (Shojaie and Jahromi, 2011;Jafarzadeh et al, 2001;Jahromi et al, 2013b;2013c). It should be noted that genetic factors as well as other traditional risk factors such as smoking, hypercholesterolemia, diabetes mellitus and hypertension may contribute to IHD development and these parameters differ among various population.…”

“…Antiphospholipid Antibodies (Abs) (aPL) in addition to repeated miscarriages and pregnancy complications (Jahromi et al, 2010c;El-Deen, 2013) participate in cardiovascular diseases (Jahromi et al, 2013a;Shojaie and Jahromi, 2011;Jahromi et al, 2013b). However their pathogenic mechanisms are still matter of investigation.…”

“…It has been demonstrated that the immunopathological factors such as anti-beta2 glycoprotein-I Ab (Shojaie and Jahromi, 2011) and Inflammatory processes (Jahromi et al, 2010b) have an important role in the initiation and development of AMI.…”